forecast
PCSK9 Should Outgrow GLP-1 Long Term
Because PCSK9 has an asymmetric benefit and risk profile, its long-run patient count and revenue should exceed GLP-1s, but adherence is harder since high LDL produces no felt symptoms.
forecastpending
Speaker
AlexEvidence Quote
“this medicine should be far bigger in terms of the number of people that are on it”
Source
Alex Karnal - The Trillion-Dollar Health Revolution - [Invest Like the Best, EP.468]— Invest Like the BestCreated: 11/14/2026, 4:24:39 AM
Your notes
Loading notes...